Clinical trial
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to…
NCT00016393 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00016393 |
|---|---|
| Title | BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ixabepilone |
| Start date | Jun 1, 2001 |
| Completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: